TV News LIES

Wednesday, May 27th

Last update01:41:42 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


British tobacco companies file objections against packaging restrictions

British tobacco ginats oppose package warningsTwo of the world's biggest tobacco companies are suing the British government for plain packaging regulations...

Brain-reading implant controls arm

brain implant controls armA man has been able to control a robotic limb with a mind-reading chip implanted in...

Tobacco firms get partial win over claims on smoking effects

Tobacco adAmerica's largest tobacco companies must inform consumers that cigarettes were designed to increase addiction, but not...

Prostate cancer gene map points way to targeted drugs

prostate cancer rosetta stoneScientists have unveiled a comprehensive genetic map of advanced prostate cancer, hailing it as the disease's...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!